GeneDx Holdings SG&A Expenses 2020-2025 | WGS
GeneDx Holdings sg&a expenses from 2020 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
| GeneDx Holdings Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $168 |
| 2023 | $195 |
| 2022 | $338 |
| 2021 | $319 |
| 2020 | $164 |
| 2019 | $69 |
| GeneDx Holdings Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025-03-31 | $50 |
| 2024-12-31 | $44 |
| 2024-09-30 | $43 |
| 2024-06-30 | $42 |
| 2024-03-31 | $40 |
| 2023-12-31 | $42 |
| 2023-09-30 | $43 |
| 2023-06-30 | $53 |
| 2023-03-31 | $57 |
| 2022-12-31 | $72 |
| 2022-09-30 | $89 |
| 2022-06-30 | $104 |
| 2022-03-31 | $72 |
| 2021-12-31 | $89 |
| 2021-09-30 | $61 |
| 2021-06-30 | $31 |
| 2021-03-31 | $137 |
| 2020-12-31 | |
| 2020-09-30 | $37 |
| 2019-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $1.887B | $0.305B |
| GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn. | |||